Eli Lilly and Company (NYSE:LLY) Shares Unloaded Rep. David Taylor

Representative David Taylor (R-Ohio) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on February 02nd, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on January 16th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Vertex Pharmaceuticals (NASDAQ:VRTX) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Medpace (NASDAQ:MEDP) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Installed Building Products (NYSE:IBP) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Prologis (NYSE:PLD) on 1/29/2026.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,003.21 on Wednesday. The company has a fifty day simple moving average of $1,054.28 and a two-hundred day simple moving average of $893.81. The company has a market cap of $948.41 billion, a price-to-earnings ratio of 49.08, a price-to-earnings-growth ratio of 0.79 and a beta of 0.39. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of Eli Lilly and Company by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after purchasing an additional 1,006,885 shares during the period. State Street Corp increased its position in Eli Lilly and Company by 0.6% during the third quarter. State Street Corp now owns 34,726,558 shares of the company’s stock worth $26,496,364,000 after buying an additional 219,590 shares during the period. Capital Research Global Investors lifted its stake in Eli Lilly and Company by 20.9% in the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after buying an additional 4,332,008 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Eli Lilly and Company by 4.1% in the third quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company’s stock valued at $11,112,164,000 after acquiring an additional 574,229 shares during the period. Finally, Laurel Wealth Advisors LLC grew its position in shares of Eli Lilly and Company by 78,621.2% during the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after acquiring an additional 11,537,661 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LLY has been the subject of several recent research reports. Jefferies Financial Group lifted their price objective on Eli Lilly and Company from $976.00 to $1,300.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Berenberg Bank raised their target price on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a report on Tuesday, December 2nd. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Loop Capital set a $950.00 price objective on shares of Eli Lilly and Company in a report on Monday, November 10th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,162.75.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Company beat expectations and raised outlook — Lilly reported Q4 revenue up ~43% and EPS growth driven by Mounjaro and Zepbound; it forecast 2026 profit above Street estimates on continued GLP‑1 demand, supporting longer‑term sales visibility. Reuters: Profit outlook
• Positive Sentiment: Quarterly beat and strong guidance lifted near‑term revenue visibility — media coverage emphasizes outsized Zepbound/Mounjaro sales that “blew past” estimates, a key driver for investor sentiment in 2026. CNBC: Earnings beat
• Positive Sentiment: Detailed results: revenue and EPS growth — company release shows Q4 revenue $19.3B and EPS +51% (reported), supporting the headline beat and cash generation. PR Newswire: Q4 results
• Positive Sentiment: Pipeline and M&A: Lilly is expanding therapeutic scope — announced a ~$1.12B deal for Seamless Therapeutics to enter the hearing‑loss/gene‑editing space, diversifying beyond GLP‑1s. Fool: Seamless deal
• Positive Sentiment: Capacity investments: $3.5B injectable manufacturing site announced — increases supply capability for GLP‑1 injectables, reducing future bottleneck risk. Becker’s: Manufacturing site
• Neutral Sentiment: Smaller strategic collaborations and minority stake moves (Zonsen PepLib collaboration, 5% Veradermics IPO stake, Repertoire collaboration) expand R&D footprint but are incremental to near‑term revenue. Yahoo: Zonsen deal
• Negative Sentiment: Competition and cost pressure caveats remain — management flagged U.S. pricing pressures; Novo’s new oral Wegovy pill and other GLP‑1 entrants raise longer‑term pricing and share risk. Reuters: Pricing pressure
• Negative Sentiment: R&D and capacity spending could weigh on margins — analysts and previews noted rising R&D/capex could temper EPS upside despite top‑line strength. Benzinga: R&D cost risk

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.